Biomaterials Firm Bolt Threads, Formerly A Unicorn, Plans SPAC Deal At A $250 Million Valuation
Share to FacebookShare to TwitterShare to LinkedinCEO Dan Widmaier talks exclusively with Forbes about going public and the ups and downs of running a synthetic biology firm. Bolt Threads, a maker of biomaterials